{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:47:18Z","timestamp":1774482438303,"version":"3.50.1"},"reference-count":72,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T00:00:00Z","timestamp":1668124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>EGFR-mediated tumors have been targeted to overcome several different malignant cancers. EGFR overexpression and mutations are directly related to the malignancy, which makes the therapy more complicated. One reason for the malignancy is the induction of AP1 followed by inflammation<jats:italic>via<\/jats:italic>IL-6 secretion. Current therapeutic strategies to overcome EGFR-mediated tumors are tyrosine kinase inhibitors (TKIs), anti-EGFR monoclonal antibodies, and the combination of these two agents with classic chemotherapy or immune checkpoint inhibitors (ICIs). Although the strategies are straightforward and have shown promising efficacy in several studies, there are still hurdles to overcoming the adverse effects and limited efficacy. This study reviews the current therapeutic strategies to target EGFR family members, how they work, and their effects and limitations. We also suggest developing novel strategies to target EGFR-mediated tumors in a novel approach. A lysosome is the main custodial staff to discard unwanted amounts of EGFR and other receptor tyrosine kinase molecules. Targeting this organelle may be a new approach to overcoming EGFR-mediated cancers.<\/jats:p>","DOI":"10.3389\/fphar.2022.1050758","type":"journal-article","created":{"date-parts":[[2022,11,11]],"date-time":"2022-11-11T05:46:15Z","timestamp":1668145575000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The lysosome as a novel therapeutic target of EGFR-mediated tumor inflammation"],"prefix":"10.3389","volume":"13","author":[{"given":"Woo Jung","family":"Sung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dohyang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anlin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Namki","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hee Min","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Heon","family":"Noh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoung Mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyun-Su","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaewoo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"259","DOI":"10.2174\/1389450053765888","article-title":"Small molecules with EGFR-TK inhibitor activity","volume":"6","author":"Albanell","year":"2005","journal-title":"Curr. Drug Targets"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4139","DOI":"10.1038\/onc.2011.572","article-title":"Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer","volume":"31","author":"Alberti","year":"2012","journal-title":"Oncogene"},{"key":"B3","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/jmcb\/mjt022","article-title":"The lysosome: From waste bag to potential therapeutic target","volume":"5","author":"Appelqvist","year":"2013","journal-title":"J. Mol. Cell. Biol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cllc.2020.09.023","article-title":"A phase II study of osimertinib combined with platinum plus pemetrexed in patients with EGFR-mutated advanced non-small-cell lung cancer: The OPAL study (NEJ032C\/LOGIK1801)","volume":"22","author":"Asahina","year":"2021","journal-title":"Clin. Lung Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature09870","article-title":"FAS and NF-\u03baB signalling modulate dependence of lung cancers on mutant EGFR","volume":"471","author":"Bivona","year":"2011","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.1093\/annonc\/mdq742","article-title":"Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: A meta-analysis","volume":"22","author":"Bria","year":"2011","journal-title":"Ann. Oncol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/s0143-4160(96)90064-0","article-title":"What is the concentration of calcium ions in the endoplasmic reticulum?","volume":"19","author":"Bygrave","year":"1996","journal-title":"Cell. Calcium"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.3389\/fonc.2020.01249","article-title":"The latest battles between EGFR monoclonal antibodies and resistant tumor cells","volume":"10","author":"Cai","year":"2020","journal-title":"Front. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1002\/jcp.20007","article-title":"Role of HER receptors family in development and differentiation","volume":"200","author":"Casalini","year":"2004","journal-title":"J. Cell. Physiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1242\/jcs.115.3.599","article-title":"pH-dependent regulation of lysosomal calcium in macrophages","volume":"115","author":"Christensen","year":"2002","journal-title":"J. Cell. Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/s0092-8674(02)01082-6","article-title":"NAADP mobilizes Ca(2+) from reserve granules, lysosome-related organelles, in sea urchin eggs","volume":"111","author":"Churchill","year":"2002","journal-title":"Cell."},{"key":"B12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/nrclinonc.2015.105","article-title":"Inflammation and cancer: Advances and new agents","volume":"12","author":"Crusz","year":"2015","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1038\/bjc.2014.555","article-title":"PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients","volume":"112","author":"D'Incecco","year":"2015","journal-title":"Br. J. Cancer"},{"key":"B14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev-pharmtox-010715-103101","article-title":"Critical functions of the lysosome in cancer biology","volume":"57","author":"Davidson","year":"2017","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"B15","first-page":"719","volume-title":"Lysosomes in applied biology and therapeutics, lysosomes in biology and patholigy","author":"Dingle","year":"1979"},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/s0962-8924(03)00005-9","article-title":"At the acidic edge: Emerging functions for lysosomal membrane proteins","volume":"13","author":"Eskelinen","year":"2003","journal-title":"Trends Cell. Biol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J. Thorac. Oncol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"12036","DOI":"10.1016\/s0021-9258(19)38504-7","article-title":"Characterization and cloning of lgp110, a lysosomal membrane glycoprotein from mouse and rat cells","volume":"265","author":"Granger","year":"1990","journal-title":"J. Biol. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell."},{"key":"B20","doi-asserted-by":"publisher","first-page":"E1653","DOI":"10.3390\/cancers11111653","article-title":"Oxygen tension regulates lysosomal activation and receptor tyrosine kinase degradation","volume":"11","author":"Hong","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1146\/annurev.genom.9.081307.164303","article-title":"Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics","volume":"9","author":"Huizing","year":"2008","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1677\/erc.0.0080151","article-title":"The ErbB receptor tyrosine family as signal integrators","volume":"8","author":"Hynes","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"B23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ceb.2008.12.010","article-title":"ErbB receptors and signaling pathways in cancer","volume":"21","author":"Hynes","year":"2009","journal-title":"Curr. Opin. Cell. Biol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.radonc.2013.06.033","article-title":"EGFR overexpressing cells and tumors are dependent on autophagy for growth and survival","volume":"108","author":"Jutten","year":"2013","journal-title":"Radiother. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"3141","DOI":"10.1074\/jbc.274.5.3141","article-title":"A leucine-based determinant in the epidermal growth factor receptor juxtamembrane domain is required for the efficient transport of ligand-receptor complexes to lysosomes","volume":"274","author":"Kil","year":"1999","journal-title":"J. Biol. Chem."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1101\/gad.17558811","article-title":"The dynamic nature of autophagy in cancer","volume":"25","author":"Kimmelman","year":"2011","journal-title":"Genes. Dev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1016\/j.bbamcr.2008.09.008","article-title":"Lysosomal involvement in cell death and cancer","volume":"1793","author":"Kirkegaard","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B28","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/32440","article-title":"A lipid associated with the antiphospholipid syndrome regulates endosome structure and function","volume":"392","author":"Kobayashi","year":"1998","journal-title":"Nature"},{"key":"B29","doi-asserted-by":"publisher","first-page":"S76","DOI":"10.21037\/atm.2019.03.6","article-title":"Combining immunotherapy and epidermal growth factor receptor kinase inhibitors: Worth the risk?","volume":"7","author":"Latif","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s12032-015-0627-6","article-title":"EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models","volume":"32","author":"Laurila","year":"2015","journal-title":"Med. Oncol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.cell.2010.06.011","article-title":"Cell signaling by receptor tyrosine kinases","volume":"141","author":"Lemmon","year":"2010","journal-title":"Cell."},{"key":"B32","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2007.12.018","article-title":"Autophagy in the pathogenesis of disease","volume":"132","author":"Levine","year":"2008","journal-title":"Cell."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/nm.1876","article-title":"Niemann-Pick disease type C1 is a sphingosine storage disease that causes deregulation of lysosomal calcium","volume":"14","author":"Lloyd-Evans","year":"2008","journal-title":"Nat. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.ceca.2011.03.010","article-title":"Lysosomal Ca(2+) homeostasis: Role in pathogenesis of lysosomal storage diseases","volume":"50","author":"Lloyd-Evans","year":"2011","journal-title":"Cell. Calcium"},{"key":"B35","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbamcr.2008.09.018","article-title":"Proteomics of the lysosome","volume":"1793","author":"Lubke","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1053\/j.seminoncol.2006.04.003","article-title":"Epidermal growth factor receptor targeting in cancer","volume":"33","author":"Mendelsohn","year":"2006","journal-title":"Semin. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"4027","DOI":"10.1200\/JCO.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): Overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1001\/jamaoncol.2017.4526","article-title":"EGFR-TKI-Associated interstitial pneumonitis in nivolumab-treated patients with non-small cell lung cancer","volume":"4","author":"Oshima","year":"2018","journal-title":"JAMA Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.annonc.2020.01.013","article-title":"Tatton: A multi-arm, phase ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer","volume":"31","author":"Oxnard","year":"2020","journal-title":"Ann. Oncol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"3852","DOI":"10.1093\/hmg\/ddr306","article-title":"Characterization of the CLEAR network reveals an integrated control of cellular clearance pathways","volume":"20","author":"Palmieri","year":"2011","journal-title":"Hum. Mol. Genet."},{"key":"B41","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1038\/onc.2015.146","article-title":"MALT1 is required for EGFR-induced NF-\u03baB activation and contributes to EGFR-driven lung cancer progression","volume":"35","author":"Pan","year":"2016","journal-title":"Oncogene"},{"key":"B42","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1677\/erc.0.0080011","article-title":"The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification","volume":"8","author":"Prenzel","year":"2001","journal-title":"Endocr. Relat. Cancer"},{"key":"B43","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/ng.438","article-title":"Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4","volume":"41","author":"Prickett","year":"2009","journal-title":"Nat. Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1200\/JCO.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.bbrc.2004.04.150","article-title":"The ErbB\/HER receptor protein-tyrosine kinases and cancer","volume":"319","author":"Roskoski","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B46","doi-asserted-by":"crossref","DOI":"10.1007\/0-387-28957-7","volume-title":"Lysosomes","author":"Saftig","year":"2005"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1042\/BST0381420","article-title":"Lysosomal membrane proteins: Life between acid and neutral conditions","volume":"38","author":"Saftig","year":"2010","journal-title":"Biochem. Soc. Trans."},{"key":"B48","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"B49","doi-asserted-by":"publisher","first-page":"a008912","DOI":"10.1101\/cshperspect.a008912","article-title":"Receptor tyrosine kinases: Legacy of the first two decades","volume":"6","author":"Schlessinger","year":"2014","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.bbamcr.2008.09.020","article-title":"Principles of lysosomal membrane degradation: Cellular topology and biochemistry of lysosomal lipid degradation","volume":"1793","author":"Schulze","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"B51","doi-asserted-by":"publisher","first-page":"75ra26","DOI":"10.1126\/scitranslmed.3002003","article-title":"Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors","volume":"3","author":"Sequist","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1126\/science.1204592","article-title":"TFEB links autophagy to lysosomal biogenesis","volume":"332","author":"Settembre","year":"2011","journal-title":"Science"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1038\/emboj.2012.32","article-title":"A lysosome-to-nucleus signalling mechanism senses and regulates the lysosome via mTOR and TFEB","volume":"31","author":"Settembre","year":"2012","journal-title":"EMBO J."},{"key":"B54","doi-asserted-by":"publisher","first-page":"7692","DOI":"10.1073\/pnas.1002753107","article-title":"ErbB3\/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation","volume":"107","author":"Shi","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/jnci\/djp280","article-title":"Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer","volume":"101","author":"Siena","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"B56","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1016\/S1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): A phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet. Oncol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1083\/jcb.112.3.469","article-title":"Effect of receptor kinase inactivation on the rate of internalization and degradation of PDGF and the PDGF beta-receptor","volume":"112","author":"Sorkin","year":"1991","journal-title":"J. Cell. Biol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s10911-008-9079-3","article-title":"Role of ErbB4 in breast cancer","volume":"13","author":"Sundvall","year":"2008","journal-title":"J. Mammary Gland. Biol. Neoplasia"},{"key":"B59","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.tcb.2015.12.006","article-title":"Stress-Induced EGFR trafficking: Mechanisms, functions, and therapeutic implications","volume":"26","author":"Tan","year":"2016","journal-title":"Trends Cell. Biol."},{"key":"B60","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/nrc3559","article-title":"Targeting the ERBB family in cancer: Couples therapy","volume":"13","author":"Tebbutt","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"B61","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.3390\/genes10010025","article-title":"Targeting DNA double-strand break repair pathways to improve radiotherapy response","volume":"10","author":"Toulany","year":"2019","journal-title":"Genes. (Basel)"},{"key":"B62","doi-asserted-by":"publisher","first-page":"3831","DOI":"10.2174\/138161212802083707","article-title":"Molecular link mechanisms between inflammation and cancer","volume":"18","author":"Vendramini-Costa","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"B63","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1002\/2211-5463.13388","article-title":"Lysosomes and lysosome-related organelles in immune responses","volume":"12","author":"Watts","year":"2022","journal-title":"FEBS Open Bio"},{"key":"B64","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/nrclinonc.2010.97","article-title":"Understanding resistance to EGFR inhibitors-impact on future treatment strategies","volume":"7","author":"Wheeler","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1172\/jci73941","article-title":"The role for autophagy in cancer","volume":"125","author":"White","year":"2015","journal-title":"J. Clin. Investig."},{"key":"B66","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1034\/j.1600-0854.2001.020103.x","article-title":"Regulation of receptor tyrosine kinase signaling by endocytic trafficking","volume":"2","author":"Wiley","year":"2001","journal-title":"Traffic"},{"key":"B67","doi-asserted-by":"publisher","first-page":"602762","DOI":"10.3389\/fonc.2020.602762","article-title":"Development of EGFR TKIs and options to manage resistance of third-generation EGFR TKI osimertinib: Conventional ways and immune checkpoint inhibitors","volume":"10","author":"Wu","year":"2020","journal-title":"Front. Oncol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.2147\/DDDT.S162214","article-title":"Safety and efficacy of durvalumab (MEDI4736) in various solid tumors","volume":"12","author":"Yang","year":"2018","journal-title":"Drug Des. devel. Ther."},{"key":"B69","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S1470-2045(12)70086-4","article-title":"Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): A phase 2 trial","volume":"13","author":"Yang","year":"2012","journal-title":"Lancet. Oncol."},{"key":"B70","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: At last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B71","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1158\/1078-0432.CCR-12-2246","article-title":"Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers","volume":"19","author":"Yu","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"B72","doi-asserted-by":"publisher","first-page":"13237","DOI":"10.1073\/pnas.1200105109","article-title":"Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling","volume":"109","author":"Zhang","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1050758\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T20:33:41Z","timestamp":1678566821000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.1050758\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,11]]},"references-count":72,"alternative-id":["10.3389\/fphar.2022.1050758"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.1050758","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,11]]},"article-number":"1050758"}}